Member (English)

Staff

MATSUYAMA Yutaka

Professor

Department of Biostatistics, School of Public Health, The University of Tokyo

matuyama [at] epistat.m.u-tokyo.ac.jp

Research

・ Design and Analysis of Clinical Trials
・ Theoretical Epidemiology
・ Causal Inference
・ Analysis of Missing Data
・ Analysis of Repeated Measures Data

Career

1992.3

Paper

  1. Takeuchi Y, Hagiwara Y, Komukai S, Matsuyama Y. Estimation of the causal effects of time-varying treatments in nested case-control studies using marginal structural Cox models. Biometrics. 2024;80:ujae005.
  2. Yokoyama R, Takeuchi Y, Kumamaru H, Matsuyama Y. The utility of the self-controlled study design for pharmacoepidemiological studies without an active comparator medication using a medical information database: An application to assess the risk of varenicline on cardiovascular outcomes. Pharmacoepidemiol Drug Saf. 32(10) 1068-1076 2023 Oct.
  3. Izumi S, Hagiwara Y, Matsuyama Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, Fukuda T, Shimozuma K. Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L. Health Qual Life Outcomes. 2023;21:3.
  4. Kurisu K, Hashimoto M, Ishizawa T, Shibayama O, Inada S, Fujisawa D, Inoguchi H, Shimoda H, Inoue S, Ogawa A, Akechi T, Shimizu K, Uchitomi Y, Matsuyama Y, Yoshiuchi K. Development of computer adaptive testing for measuring depression in patients with cancer. Scientific Report 2022; 12(1): 8247.
  5. Nishi D, Imamura K, Watanabe K, Obikane E, Sasaki N, Yasuma N, Sekiya Y, Matsuyama Y, Kawakami N. The preventive effect of internet-based cognitive behavioral therapy for prevention of depression during pregnancy and in the postpartum period (iPDP): a large scale randomized controlled trial. Psychiatry Clin Neurosci. 2022; 76(11): 570-578.
  6. Imamura K, Sasaki N, Sekiya Y, Watanabe K, Sakuraya A, Matsuyama Y, Nishi D, Kawakami N. The Effect of the Imacoco Care Psychoeducation Website on Improving Psychological Distress Among Workers During the COVID-19 Pandemic: Randomized Controlled Trial. JMIR Form Res. 2022; 6(3): e33883.
  7. Miyamoto S, Yamazaki T, Shimizu K, Matsubara T, Kage H, Watanabe K, Kobo H, Matsuyama Y, Rodin G, Yoshiuchi K. A brief, manualized, and semi-structured individual psychotherapy program for advanced cancer patients in Japan: study protocol for Managing Cancer and Living Meaningfully (CALM) phase 2 trial. BMJ Open 2022; 12(3): e056136.
  8. Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S. Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013). Hepatol Res. 2022; 52(1): 5-66.
  9. Sugawara Y, Hirakawa Y, Mise K, Kashiwabara K, Hanai K, Yamaguchi S, Katayama A, Onishi Y, Yoshida Y, Kashihara N, Matsuyama Y, Babazono T, Nangaku M, Wada J. Analysis of inflammatory cytokines and estimated glomerular filtration rate decline in Japanese patients with diabetic kidney disease: a pilot study. Biomark Med. 2022; 16(10): 759-770.
  10. Kokubo T, Kodera S, Sawano S, Katsushika S, Nakamoto M, Takeuchi H, Kimura N, Shinohara H, Matsuoka R, Nakanishi K, Nakao T, Higashikuni Y, Takeda N, Fujiu K, Daimon M, Akazawa H, Morita H, Matsuyama Y, Komuro I. Automatic Detection of Left Ventricular Dilatation and Hypertrophy from Electrocardiograms Using Deep Learning. Int Heart J. 2022; 63(5): 939-947.
  11. Ecker L, Lee J, Saadat LV, Aparicio T, Buisman FE, Balachandran VP, Drebin JA, Hasegawa K, Jarnagin WR, Kemeny NE, Kingham TP, Koerkamp BG, Kokudo N, Matsuyama Y, Portier G, Saltz LB, Soares KC, Wei AC, Gonen M, D’Angelica MI. Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. Lancet Oncol 2022; 23(10): 1332-1342.
  12. Takayama T, Hasegawa K, Izumi N, Kudo M, Shimada M, Yamanaka N, Inomata M, Kaneko S, Nakayama H, Kawaguchi Y, Kashiwabara K, Tateishi R, Shiina S, Koike K, Matsuyama Y, Omata M, Makuuchi M, Kokudo N. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF-Trial). Liver Cancer 2022; 11: 209-218.
  13. Inai K, Inuzuka R, Ono H, Nii M, Ohtsuki S, Kurita Y, Takeda A, Hirono K, Takei K, Yasukouchi S, Yoshikawa T, Furutani Y, Shimada E, Shinohara T, Shinozaki T, Matsuyama Y, Senzaki H, Nakanishi T. Predictors of long-term mortality among perioperative survivors of Fontan operation. Eur Heart J. 2022; 43(25): 2373-2384.
  14. Ishii J, Kashiwabara K, Ozaki Y, Takahashi H, Kitagawa F, Nishimura H, Ishii H, Iimuro S, Kawai H, Muramatsu T, Naruse H, Iwata H, Tanizawa-Motoyama S, Ito H, Watanabe E, Matsuyama Y, Fukumoto Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Hokimoto S, Miyauchi K, Ohtsu H, Izawa H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Matsuzaki M, Nagai R. Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease. J Atheroscler Thromb. 2022; 29(10): 1458-1474.
  15. Matsumoto Y, Umemura S, Okizaki A, Fujisawa D, Kobayashi N, Tanaka Y, Sasaki C, Shimizu K, Ogawa A, Kinoshita H, Uchitomi Y, Yoshiuchi K, Matsuyama Y, Morita T, Goto K, Ohe Y. Early specialized palliative care for patients with metastatic lung cancer receiving chemotherapy: a feasibility study of a nurse-led screening-triggered programme. Japanese Journal of Clinical Oncology 2022; 52(4): 375-382.
  16. Sawamoto R, Oba K, Matsuyama Y. Bayesian adaptive randomization design incorporating propensity score-matched historical controls. Pharm Stat. 2022 Sep;21(5):1074-1089. doi: 10.1002/pst.2203.
  17. Fujita S, Cencini M, Buonincontri G, Takei N, Schulte RF, Fukunaga I, Uchida W, Hagiwara A, Kamagata K, Hagiwara Y, Matsuyama Y, Abe O, Tosetti M, Aoki S. Simultaneous Relaxometry and Morphometry of Human Brain Structures with Three-dimensional Magnetic Resonance Fingerprinting: A Multicenter, Multiplatform, Multi-field-strength Study. Cereb Cortex. 2022. doi: 10.1093/cercor/bhab259. Online ahead of print.
  18. Fuyama K, Hagiwara Y, Matsuyama Y. A simulation study of regression approaches for estimating risk ratios in the presence of multiple confounders. Emerg Themes Epidemiol. 2021;18:18.
  19. Kokudo T, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Ishihara S, Makuuchi M, Kokudo N, Hasegawa K. Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases. Surgery. 2021; 170(4): 1151-1154.
  20. Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S. Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011). Hepatol Res. 2021; 51(4): 355-405.
  21. Nii M, Inuzuka R, Inai K, Shimada E, Shinohara T, Kogiso T, Ono H, Ootsuki S, Kurita Y, Takeda A, Hirono K, Takei K, Yasukochi S, Yoshikawa T, Furutani Y, Shinozaki T, Matsuyama Y, Senzaki H, Tokushige K, Nakanishi T. Incidence and expected probability of liver cirrhosis and hepatocellular carcinoma after fontan pperation. Circulation. 2021; 144(25): 2043-2045.
  22. Yamamuro S, Shinozaki T, Imuro S, Matsuyama Y. Mediational g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin’s effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics. Statistical Methods in Medical Research 2021; 30(8): 1782-1799.
  23. Aramaki O, Takayama T, Moriguch I M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M; ACE 500 study group. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. European Journal of Cancer 2021; 157: 373-382.
  24. Aoki T, Kubota K, Kubo S, Eguchi S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, Kudo M. Analysis of patient outcome after non-curative resection for hepatocellular carcinoma using nationwide survey data in Japan. World Journal of Surgery 2021; 45(2): 607-614.
  25. Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol. 2021; 56(3): 261-273.
  26. Takeuchi Y, Ogawa M, Hagiwara Y, Matsuyama Y. Non-parametric approach for frequentist multiple imputation in survival analysis with missing covariates. Stat Methods Med Res. 2021; 30(7): 1691-1707.
  27. Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giuliante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N. Effect of diameter and number of hepatocellular carcinomas on survival after resection, trans-arterial chemoembolization, and ablation. Am J Gastroenterol. 2021. doi: 10.14309/ajg.0000000000001256.
  28. Takeuchi Y, Kumamaru H, Hagiwara Y, Matsui H, Yasunaga H, Miyata H, Matsuyama Y. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database. Diabetes Obes Metab. 2021; 23(6): 1379-1388.
  29. Taniguchi Y, Kitamura A, Abe T, Kojima G, Shinozaki T, Seino S, Yokoyama Y, Nofuji Y, Ikeuchi T, Matsuyama Y, Fujiwara Y, Shinkai S. Associations of aging trajectories for an index of frailty score with mortality and medical and long-term care costs among older Japanese undergoing health checkups. Geriatr Gerontol Int. 2020; 20(11): 1072-1078.
  30. Nishi D, Imamura K, Watanabe K, Obikane E, Sasaki N, Yasuma N, Sekiya Y, Matsuyama Y, Kawakami N. Internet-based cognitive-behavioural therapy for prevention of depression during pregnancy and in the post partum (iPDP): a protocol for a large-scale randomised controlled trial. BMJ Open. 2020; 10(5): e036482.
  31. Kawahara T, Shinozaki T, Matsuyama Y. Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin. BMC Med Res Methodol. 2020; 20(1): 204.
  32. Yamashita S, Shinozaki T, Murata H, Matsuyama Y, Babazono T. Panel of novel urine biomarkers for incident microalbuminuria in people with type 2 diabetes mellitus. Diabetic Medicine 2020; 37: 1910-8.
  33. Watanabe Y, Matsuyama Y, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Kudo M. Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan. Surgery. 2020; 167(5): 793-802.
  34. Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M; Liver Cancer Study Group of Japan. Liver resection for multiple hepatocellular carcinomas: A Japanese nationwide survey. Annals of Surgery 2020; 272(1): 145-154.
  35. Yoshida Y, Kashiwabara K, Hirakawa Y, Tanaka T, Noso S, Ikegami H, Ohsugi M, Ueki K, Mita T, Watada H, Koya D, Mise K, Wada J, Shimizu M, Wada T, Ito Y, Narita I, Kashihara N, Nangaku M, Matsuyama Y. Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. BMJ Open Diabetes Res Care. 2020; 8(1): e000902.
  36. Usui T, Yoshida Y, Nishi H, Yanagimoto S, Matsuyama Y, Nangaku M. Diagnostic accuracy of urine dipstick for proteinuria category in Japanese workers. Clin Exp Nephrol. 2020; 24(2): 151-156.
  37. Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Takayama T. Report of the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res. 2020; 50(1): 15-46.
  38. Yoshida M, Miura Y, Okada S, Yamada M, Kagaya H, Saitoh E, Kamakura Y, Okawa Y, Matsuyama Y, Sanada H. Effectiveness of swallowing care on safe oral intake using ultrasound-based observation of residues in the epiglottis valley: A pragmatic, quasi-experimental study. Healthcare 2020; 8(1): 50.
  39. Takeuchi Y, Kashiwabara K, Hosoi H, Imai H, Matsuyama Y. Longitudinal effects of a nationwide lifestyle intervention program on cardiometabolic outcomes in Japan: An observational cohort study. Prev Med. 2020; 141: 106301.
  40. Yamada G, Hagiwara Y, Kimura T, Takeuchi Y, Oba K, Masuda K, Matsuyama Y. Impact of body weight gain on the incidence of non-alcoholic fatty liver disease in non-obese Japanese individuals. Am J Gastroenterol. 2021; 116(4): 733-740.
  41. Miyasato Y, Oba K, Yasuno S, Matsuyama Y, Masuda I. Associations between visceral obesity and renal impairment in health checkup participants: a retrospective cohort study. Clin Exp Nephrol. 2020 Oct;24(10):935-945. doi: 10.1007/s10157-020-01921-9.
  42. Hagiwara Y, Shinozaki T, Mukai H, Matsuyama Y. Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: a two-stage stochastic dynamic treatment regime approach. Biometrics. 2020. doi: 10.1111/biom.13296. Online ahead of print.
  43. Kozuma K, Kozuma K, Shinozaki T, Kashiwabara K, Oba K; Xience P. M. S. Group; PROMUS Element/Element Plus P. M. S. Group, Matsuyama Y. Multivariable Prediction Model to Estimate the Probability of Restenosis at Proximal Edge After 2nd-generation Drug-Eluting-Stent Implantation: Development and Internal Validation Using a Quantitative Coronary Angiography From the Post-Marketing Surveillance Studies of Everolimus-Eluting Stent in Japan. Cardiovasc Interv Ther. 2020 Apr 18.
  44. Usui T, Yoshida Y, Nishi H, Yanagimoto S, Matsuyama Y, Nangaku M. Diagnostic accuracy of urine dipstick for proteinuria category in Japanese workers. Clin Exp Nephrol. 2020; 24(2): 151-156.
  45. Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Takayama T. Report of the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res. 2020; 50(1): 15-46.
  46. Yoshida M, Miura Y, Okada S, Yamada M, Kagaya H, Saitoh E, Kamakura Y, Okawa Y, Matsuyama Y, Sanada H. Effectiveness of swallowing care on safe oral intake using ultrasound-based observation of residues in the epiglottis valley: A pragmatic, quasi-experimental study. Healthcare 2020; 8(1).
  47. Taniguchi Y, Kitamura A, Kaito S, Yokoyama Y, Yokota I, Shinozaki T, Seino S, Murayama H, Matsuyama Y, Ikeuchi T, Fujiwara Y, Shinkai S. Albumin and hemoglobin trajectories and incident disabling dementia in community-dwelling older Japanese. Dement Geriatr Cogn Disord. 2019; 47: 233-242.
  48. Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019; 49(10): 1109-1113.
  49. Taniguchi Y, Kitamura A, Ishizaki T, Fujiwara Y, Shinozaki T, Seino S, Mitsutake S, Suzuki H, Yokoyama Y, Abe T, Ikeuchi T, Yokota I, Matsuyama Y, Shinkai S. Association of trajectories of cognitive function with cause-specific mortality and medical and long-term care costs. Geriatr Gerontol Int. 2019; 19(12): 1236-1242.
  50. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Eguchi S, Yamashita T, Kudo M. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer 2019; 8(5): 403-411.
  51. Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan. Treatment optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort. Ann Surg. 2019; 270(1): 121-130.
  52. Takao T, Matsuyama Y, Suka M, Yanagisawa H, Kasuga M. Analysis of the duration and extent of the legacy effect in patients with type 2 diabetes: A real-world longitudinal study. J Diabetes Complications. 2019; 33(8): 516-522.
  53. Kaibori M, Yoshii K, Yokota I, Hasegawa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan. Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: Report of a Japanese nationwide survey. Annals of Surgery 2019; 269(4): 692-699.
  54. Taniguchi Y, Kitamura A, Nofuji Y, Ishizaki T, Seino S, Yokoyama Y, Shinozaki T, Murayama H, Mitsutake S, Amano H, Nishi M, Matsuyama Y, Fujiwara Y, Shinkai S. Association of trajectories of higher-level functional capacity with mortality and medical and long-term care costs among community-dwelling older Japanese. J Gerontol A Biol Sci Med Sci. 2019; 74(2): 211-218.
  55. Hagiwara Y, Shinozaki T, Matsuyama Y. G‐estimation of structural nested restricted mean time lost models to estimate effects of time‐varying treatments on a failure time outcome. Biometrics. 2020;76:799–810.
  56. Kozuma Kayoko, Shinozaki T, Kozuma Ken, Kashiwabara K, Oba K, Aoki J, Awata M, Nanasato M, Shiode N, Tanabe K, Yamaguchi J, Kimura T, Matsuyama Y. Impact of residual stenosis on the angiographic edge restenosis of second-generation drug-eluting stent -integrated analysis of quantitative coronary angiography from four post-marketing surveillances of cobalt-chromium everolimus-eluting stent in Japan-. Int Heart J. 2019, in press.
  57. Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Matsuyama Y, Unno M; Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019; 49(2): 190-194.
  58. Ikuta K, Hanashi H, Hirai K, Ota Y, Matsuyama Y, Shimura A, Terauchi M, Momoeda M. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol. 2019; 109(1): 41-49.
  59. Yokota I, Matsuyama Y. Dynamic prediction of repeated events data based on landmarking model: application to colorectal liver metastases data. BMC Med Res Methodol. 2019; 19(1): 31.
  60. Iwata A, Iwatsubo T, Ihara R, Suzuki K, Matsuyama Y, Tomita N, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H; Alzheimer's Disease Neuroimaging Initiative; Japanese Alzheimer’s Disease Neuroimaging Initiative. Effects of sex, educational background, and chronic kidney disease grading on longitudinal cognitive and functional decline in patients in the Japanese Alzheimer's Disease Neuroimaging Initiative study. Alzheimers Dement 2018; 4: 765-774.
  61. Imamura K, Furukawa TA, Matsuyama Y, Shimazu A, Kuribayashi K, Kasai K, Kawakami N. Differences in the effect of internet-based cognitive behavioral therapy for improving nonclinical depressive symptoms among workers by time preference: Randomized controlled trial. J Med Internet Res. 2018; 10; 20(8):e10231.
  62. Yamaguchi K, Kamatari Y, Ono F, Shibata H, Fuse T, Elhelaly A, Fukuoka M, Kimura T, Hosokawa-Muto J, Ishikawa T, Tobiume M, Takeuchi Y, Matsuyama Y, Ishibashi D, Nishida N, Kuwata K. A designer molecular chaperone against transmissible spongiform encephalopathy slows down the progression of the disease in mice and macaques. Nature Biomed Eng. 2019; 3: 206–219.
  63. Okui T, Matsuyama Y, Nakaji S. A new association analysis method for gut microbial compositional data using ensemble learning. Japanese Journal of Biometrics 2018; 39(2): 55-84.
  64. Takeuchi Y, Shinozaki T, Kumamaru H, Hiramatsu T, Matsuyama Y. Analyzing intent-to-treat and per-protocol effects on safety outcomes using a medical information database: An application to the risk assessment of antibiotic-induced liver injury. Expert Opin Drug Saf. 2018; 17(11): 1071–1079.
  65. Kashiwabara K, Matsuyama Y. Reasonable two-stage adaptive designs for single-arm phase II clinical trials. Pharm Stat 2018; 17(6): 770-780.
  66. Hagiwara Y, Fukuda M, Matsuyama Y. The number of events per confounder for valid estimation of risk difference using modified least-squares regression. Am J Epidemiol. 2018;187:2481-2490.
  67. Taniguchi Y, Kitamura A, Shinozaki T, Seino S, Yokoyama Y, Narita M, Amano H, Matsuyama Y, Fujiwara Y, Shinkai S. Trajectories of arterial stiffness and all-cause mortality among community-dwelling older Japanese. Geriatr Gerontol Int. 2018;18(7):1108-13,
  68. Taniguchi Y, Kitamura A, Nofuji Y, Ishizaki T, Seino S, Yokoyama Y, Shinozaki T, Murayama H, Mitsutake S, Amano H, Nishi M, Matsuyama Y, Fujiwara Y, Shinkai S. Association of trajectories of higher-level functional capacity with mortality and medical and long-term care costs among community-dwelling older Japanese. J Gerontol A Biol Sci Med Sci. 2018;74(2):211-218..
  69. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N, Liver Cancer Study Group of Japan. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analyzed with propensity score weighting. Liver Int. 2018;38:484-493.
  70. Takeuchi Y, Shinozaki T, Matsuyama Y. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. BMC Med Res Methodol. 2018; 18: 4.
  71. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M, The Liver Cancer Study Group of Japan. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 2017; 6(4): 325–336.
  72. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N; Liver Cancer Study Group of Japan. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology. 2017;66(2):510-7.
  73. Tanaka S, Matsuyama Y, Ohashi Y. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial. Stat Med. 2017;36(19):2963-77.
  74. Notake T, Kobayashi A, Shinkawa H, Kawahara T, Shimizu A, Yokoyama T, Hasegawa K, Kokudo N, Matsuyama Y, Makuuchi M, Miyagawa SI. Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. Int J Clin Oncol. 2017;22(4):715-25.
  75. Ueno M, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, Ioka T, Oh DY, Ichikawa W, Okusaka T, Matsuyama Y, Arai D, Chen LT, Park YS, Furuse J. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemother Pharmacol. 2017;80(2):307-15.
  76. Mukai H, Hagiwara Y, Imi K, Isaka H, Watanabe K, Matsuyama Y for the SELECT BC Study Group. The impact of treatment preferences in second-line chemotherapy on the prognosis of HER2-negative metastatic breast cancer. Oncology. 2017;93:315-322.
  77. Shinozaki T, Mansournia MA, Matsuyama Y. On hazard ratio estimators by proportional hazards models in matched-pair cohort studies. Emerg Themes Epidemiol. 2017;14:6.
  78. Shinozaki T, Hagiwara Y, Matsuyama Y. Re. Biases in randomized trials: a conversation between trialists and epidemiologists (Letter). Epidemiology. 2017; 28(4): e40-e41.
  79. Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M; Liver Cancer Study Group of Japan. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol. 2017;52(10):1112-21.
  80. Kozuma K, Kashiwabara K, Shinozaki T, Kozuma K, Oba K, Matsuyama Y. Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA). Int J Cardiovasc Imaging. 2017;33(6):779-787. doi: 10.1007/s10554-017-1068-4.
  81. Taniguchi Y, Kitamura A, Murayama H, Amano H, Shinozaki T, Yokota I, Seino S, Nofuji Y, Nishi M, Yokoyama Y, Matsuyama Y, Fujuwara Y, Shinkai S. Mini-Mental State Examination Score Trajectories and Incident Disabling Dementia Among Community-Dwelling Older Japanese. Geriatr Gerontol Int. 2017;17(11):1928-35.
  82. Taniguchi Y, Fujiwara Y, Murayama H, Yokota I, Matsuo E, Seino S , Nofuji Y, Nishi M, Matsuyama Y, Shinkai S. Prospective Study of Trajectories of Physical Performance and Mortality Among Community-Dwelling Older Japanese. J Gerontol A Biol Sci Med Sci. 2016; 71:1492-1499.
  83. Taniguchi Y, Kitamura A, Seino S, Murayama H, Amano H, Nofuji Y, Nishi M, Yokoyama Y, Shinozaki T, Yokota I, Matsuyama Y, Fujiwara Y, Shinkai S. Gait Performance Trajectories and Incident Disabling Dementia Among Community-Dwelling Older Japanese. J Am Med Dir Assoc. 2017;18(2):192.e13-192.e20.
  84. Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Watanabe T, Makuuchi M, Kokudo N. Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: A randomized controlled trial. PLoS One. 2016; 11(9): e0162400.
  85. Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016; 46(5): 372-90.
  86. Moriya J, Matsuyama Y. Estimating treatment effect of high hemoglobin using the principal stratification approach. Jpn J Biometrics. 2016; 37: 7-22.
  87. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N; Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016; 65(5): 938-943.
  88. Yoshida M, Matsuyama Y. Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry. J Biopharm Stat. 2016; 26(5): 842-58.
  89. Kitahara H, Waseda K, Sakamoto K, Yamada R, Huang CC, Nakatani D, Sakata K, Kawarada O, Yock PG, Matsuyama Y, Yokoi H, Nakamura M, Muramatsu T, Nanto S, Fitzgerald PJ, Honda Y. Impact of attenuated-signal plaque observed by intravascular ultrasound on vessel response after drug-eluting stent implantation. Atherosclerosis. 2017; 259: 68-74.
  90. Zhu Y, Chen CY, Matsuyama Y, Ohashi Y, Franklin JM, Setoguchi S. Comparative validity of methods to select appropriate cutoff weight for probabilistic linkage without unique personal identifiers. Pharmacoepidemiol Drug Saf. 2016; 25(4): 444-52.
  91. Takahashi M, Hasegawa K, Oba M, Saiura A, Arita J, Sakamoto Y, Shinozaki E, Mizunuma N, Matsuyama Y, Kokudo N. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases. Invest New Drugs. 2016; 34(4): 468-73.
  92. Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. Liver Cancer. 2016; 5(3): 175-189.
  93. Iijima R, Nakamura M, Matsuyama Y, Muramatsu T, Yokoi H, Hara H, Okada H, Ochiai M, Suwa S, Hozawa H, Kawai K, Awata M, Mukawa H, Fujita H, Nanto S; J-DESsERT. Effect of optimal medical therapy before procedures on outcomes in coronary patients treated with drug-eluting stents. Am J Cardiol. 2016; 118(6): 790-6.
  94. Kokudo T, Hasegawa K, Amikura K, Uldry E, Shirata C, Yamaguchi T, Arita J, Kaneko J, Akamatsu N, Sakamoto Y, Takahashi A, Sakamoto H, Makuuchi M, Matsuyama Y, Demartines N, Malagó M, Kokudo N, Halkic N. Assessment of preoperative liver function in patients with hepatocellular carcinoma - The albumin-indocyanine green evaluation (ALICE) grade. PLoS One. 2016; 11(7): e0159530.
  95. Ichida A, Hasegawa K, Takayama T, Kudo H, Sakamoto Y, Yamazaki S, Midorikawa Y, Higaki T, Matsuyama Y, Kokudo N. Randomized clinical trial comparing two vessel-sealing devices with crush clamping during liver transection. Br J Surg. 2016; 103(13): 1795-1803.
  96. Takao T, Suka M, Yanagisawa H, Matsuyama Y, Iwamoto Y. Predictive ability of visit-to-visit variability in HbA1c and systolic blood pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes. Diabetes Res Clin Pract. 2017; 128: 15-23.
  97. Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016; 5(3): 190-7.
  98. Nakamura M, Muramatsu T, Yokoi H, Okada H, Ochiai M, Suwa S, Hozawa H, Kawai K, Awata M, Mukawa H, Fujita H, Shiode N, Asano R, Tsukamoto Y, Yamada T, Yasumura Y, Ohira H, Miyamoto A, Takashima H, Ogawa T, Ito S, Matsuyama Y, Nanto S; J-DESsERT investigators. Three-year follow-up outcomes of SES and PES in a randomized controlled study stratified by the presence of diabetes mellitus: J-DEsSERT trial. International Journal of Cardiology 2016; 208: 4-12.
  99. Shindoh J, Makuuchi M, Matsuyama Y, Mise Y, Arita J, Sakamoto Y, Hasegawa K, Kokudo N. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. Journal of Hepatology 2016; 64(3): 594-600.
  100. Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O; Liver Cancer Study Group of Japan. Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer 2016; 122(1): 61-70.
  101. Omichi K, Shindoh J, Yamamoto S, Matsuyama Y, Akamatsu N, Arita J, Kaneko J, Sakamoto Y, Hasegawa K, Kokudo N. Postoperative outcomes for patients with non-B non-C hepatocellular carcinoma: A subgroup analysis of patients with a history of hepatitis B infection. Annals of Surgical Oncology 2015; 22(Suppl 3): 1034-1040.
  102. TakaoT, Matsuyama Y, Suka M, Yanagisawa H, Iwamoto Y. The combined effect of visit-to-visit variability in HbA1c and systolic blood pressure on the incidence of cardiovascular events in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2015 Nov 13;3(1):e000129.
  103. Kokudo T, Hasegawa K, Uldry E, Matsuyama Y, Kaneko J, Akamatsu N, Aoki T, Sakamoto Y, Demartines N, Sugawara Y, Kokudo N, Halkic N. A new formula for calculating standard liver volume for living donor liver transplantation without using body weight. Journal of Hepatology 2015; 63(4): 848-854.
  104. Zhu Y, Matsuyama Y, Ohashi Y, and Setoguchi S. When to conduct probabilistic linkage vs. deterministic linkage? : A simulation study. Journal of Biomedical Informatics 2015; 56: 80-86.
  105. Gotoda T, Ishikawa H, Ohnishi H, Sugano K, Kusano C, Yokoi C, Matsuyama Y, Moriyasu F. Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy. Gastric Cancer 2015; 18(3): 605-611.
  106. Ng CF, Matsuyama y, and Ohashi Y. Case-only method to estimate the relative incidence of adverse events for comparison of two treatments: Application in disseminated intravascular coagulation patients. Japanese Journal of Biometrics 2015; 36: 13-24.
  107. Takao T, Kimura K, Suka M, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y. Relationships between the risk of cardiovascular disease in type 2 diabetes patients and both visit-to-visit variability and time-to-effect differences in blood pressure. Journal of Diabetes and Its Complications 2015; 29(5): 699-706.
  108. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Kasai K. Effects of an internet-based cognitive behavioural therapy intervention on preventing major depressive episodes among workers: a protocol for a randomised controlled trial. BMJ Open 2015; 5(5): e007590.
  109. Nakamura M, Muramatsu T, Yokoi H, Okada H, Ochiai M, Suwa S, Hozawa H, Kawai K, Awata M, Mukawa H, Fujita H, Shiode N, Asano R, Tsukamoto Y, Yamada T, Yasumura Y, Ohira H, Miyamoto A, Takashima H, Ogawa T, Matsuyama Y, Nanto S; J-DESsERT investigators. Outcomes of the largest multi-center trial stratified by the presence of diabetes mellitus comparing sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with coronary artery disease. The Japan drug-eluting stents evaluation: a randomized trial (J-DESsERT). Cardiovascular Intervention and Therapeutics 2015; 30(2): 103-114.
  110. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatology Research 2015; 45(2): 123-127.
  111. Kimura T, Deshpande GA, Urayama KY, Masuda K, Fukui T, Matsuyama Y. Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals. Journal of Gastroenterology and Hepatology 2015; 30(5): 909-917.
  112. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Umanodan R, Kawakami S, Kasai K. Effects of an internet-based cognitive behavioral therapy intervention on improving work engagement and other work-related outcomes: an analysis of secondary outcomes of a randomized controlled trial. Journal of Occupational and Environmental Medicine 2015; 57(5): 578-584.
  113. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Annals of Surgery 2015; 261(3): 513-520.
  114. Shinozaki T, Matsuyama Y. Doubly robust estimation of standardized risk difference and ratio in the exposed population. Epidemiology. 2015;26(6):873-7.
  115. Taniguchi Y, Fujiwara Y, Nofuji Y, Nishi M, Murayama H, Seino S, Tajima R, Matsuyama Y, Shinkai S. Prospective study of arterial stiffness and subsequent cognitive decline among community-dwelling older Japanese. Journal of Epidemiology 2015; 25(9): 592-599.
  116. Kitai S, Kudo M, Izumi N, Kaneko S, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Kadoya M, Matsuyama Y, Matsunaga T. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey. Digestive diseases 2014; 32(6):717-724.
  117. Otsuka M, Yokoi H, Matsuyama Y, Hayashi Y, Shiode N, Masaoka Y, Okimoto T, Tamekiyo H, Kawase T, Yamane K, Kagawa Y, Nakamura M, Muramatsu T, Nanto S; J-DESsERT investigators. Comparison of sirolimus- and paclitaxel-eluting stents in patients with moderate renal insufficiency: results from the J-DESsERT trial. Cardiovascular Revascularization Medicine 2014; 15: 323-328.
  118. Taguri M, Matsuyama Y, Ohashi Y. Model selection criterion for causal parameters in structural mean models based on a quasi-likelihood. Biometrics 2014; 70(3): 721–730.
  119. Takao T, Matsuyama Y, Suka M, Yanagisawa H, Kikuchi M, Kawazu S. Time-to-effect relationships between systolic blood pressure and the risks of nephropathy and retinopathy in patients with type 2 diabetes. Journal of Diabetes and its Complications 2014; 28(5): 674-678.
  120. Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Association between HbA1c variability and mortality in patients with type 2 diabetes. Journal of Diabetes and Its Complications 2014; 28(4): 494-499.
  121. Kashiwabara K, Matsuyama Y, Ohashi Y. A Bayesian stopping rule for sequential monitoring of serious adverse events. Therapeutic Innovation and Regulatory Science 2014; 48: 444-452.
  122. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Umanodan R, Kawakami S, Kasai K. Effects of an Internet-based cognitive behavioral therapy (iCBT) program in Manga format on improving subthreshold depressive symptoms among healthy workers: a randomized controlled trial. PLoS One 2014; 9(5): e97167.
  123. Shinozaki T, Matsuyama Y, Ohashi Y. Estimation of controlled direct effects in time-varying treatments using structural nested mean models: application to a primary prevention trial for coronary events with pravastatin. Stat Med. 2014;33(18):3214-28.
  124. Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes. Journal of Diabetes and its Complications 2014; 28(2): 185-190
  125. Aramaki O, Takayama T, Higaki T, Nakayama H, Ohkubo T, Midorikawa Y, Moriguchi M, Matsuyama Y. Decreased blood loss reduces postoperative complications in resection for hepatocellular carcinoma. Journal of Hepato-biliary Pancreatic Sciences 2014; 21(8): 585-591.
  126. Oba M, Hasegawa K, Matsuyama Y, Shindoh J, Mise Y, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Annals of Surgical Oncology 2014; 21(6): 1817-1824.
  127. Naito S, Imamura H, Tukada A, Matsuyama Y, Yoshimoto J, Sugo H, Ishizaki Y, Kawasaki S. Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis viral infection status. Liver International 2014; 34(5): 802-813.
  128. Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Makuuchi M; for the Liver Cancer Study Group of Japan. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: An analysis of 1160 cases from a nationwide survey. Annals of Surgery 2014; 259(3): 532-542.
  129. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Annals of Surgery 2014; 259(2): 336-345.
  130. Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y. Impact of histologically confirmed lymph node metastases on patient survival after surgical resection for hepatocellular carcinoma: Report of a Japanese nationwide survey. Annals of Surgery 2014; 259(1): 166-170.
  131. Kato H, Nakagami G, Iwahira Y, Otani R, Nagase T, Iizaka S, Tamai N, Matsuyama Y, Sanada H. Risk factors and risk scoring tool for infection during tissue expansion in tissue expander and implant breast reconstruction. The Breast Journal 2013; 19(6): 618-826.
  132. Fujita R, Iimuro S, Shinozaki T, Sakamaki K, Uemura Y, Takeuchi A, Matsuyama Y, Ohashi Y. Decreased duration of acute upper respiratory tract infections with daily intake of fermented milk: A multicenter, double-blinded, randomized comparative study in users of day care facilities for the elderly population. Am J Infect Control. 2013; 41(12): 1231-1235.
  133. Taguri M, Matsuyama Y. Comments on ‘An information criterion for marginal structural models’ by R. W. Platt, M. A. Brookhart, S. R. Cole, D. Westreich, and E. F. Schisterman. Statistics in Medicine 2013; 32: 3590-3591.
  134. Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Matsuyama Y, Omata M, Ohtomo K, Koike K. CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: A randomized controlled trial. The American Journal of Gastroenterology 2013; 108(8): 1305-1313.
  135. Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y. Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey. Journal of Hepatology 2013; 58(4):724-729.
  136. Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. Journal of Clinical Oncology 2013; 31(6): 766-773.
  137. Seyama Y, Imamura H, Inagaki1 Y, Matsuyama Y, Tang W, Makuuchi M, Kokudo N. Intermittent clamping is superior to ischemic preconditioning and its effect is more marked with shorter clamping cycles in the rat liver. Journal of Gastroenterology 2013; 48(1): 115-124.
  138. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Ichida T, Nakashima O, Matsui O, Izumi N, Ku Y, Kokudo N, Makuuchi M for the Liver Cancer Study Group of Japan. Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm. Liver International 2013; 33(5): 762-770.
  139. Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H, for the Japanese Elderly Diabetes Intervention Trial Research Group. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model. Geriatr Gerontol Int. 2012; 12 (Suppl. 1): S88-S102.
  140. Taguri M, Matsuyama Y, Ohashi Y, Harada A and Ueshima H. Doubly robust estimation of the generalized impact fraction. Biostatistics 2012; 13: 455-467.
  141. Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. Superselective transarterial chemoembolization for hepatocellular carcinoma: Validation of treatment algorithm proposed by Japanese guidelines. Journal of Hepatology 2012; 56(4): 886-892.
  142. Isayama H, Yasuda I, Ryozawa S, Maguchi H, Igarashi Y, Matsuyama Y, Katanuma A, Hasebe O, Irisawa A, Itoi T, Mukai H, Arisaka Y, Okushima K, Uno K, Kida M, Tamada K. Results of a Japanese multicenter, randomized trial of endoscopic stenting for non-resectable pancreatic head cancer (JM-TEST): Covered wallstent versus doublelayer stent. Digestive Endoscopy 2011; 23(4): 310-315.
  143. Higashi T, Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Sobue T; the Liver Cancer Study Group of Japan. Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatology Research 2011; 41(12): 1208-1215.
  144. Aoki T, Imamura H, Matsuyama Y, Kishi Y, Kobayashi T, Sugawara Y, Makuuchi M and Kokudo N. Convergence process of volumetric liver regeneration after living-donor hepatectomy. Journal of Gastrointestinal Surgery 2011; 15:1594-1601.
  145. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M; for the Liver Cancer Study Group of Japan. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. British Journal of Surgery 2011; 98(4): 552-557.
  146. Araki Y, Matsuyama Y, Kobayashi Y, Toyokawa S, Inoue K, Suzuki S and Makimoto A. Secondary neoplasms after retinoblastoma treatment: Retrospective cohort study of 754 patients in Japan. Japanese Journal of Clinical Oncology 2011; 41(3): 373-379.
  147. Takeuchi A, Matsuyama Y, Ohashi Y, and Ueshima H. Monte Carlo sensitivity analysis for adjusting multiple-bias in the longitudinal cardiovascular study. Japanese Journal of Biometrics 2010; 31: 63-76.
  148. Taguri M, Matsuyama Y, Ohashi Y, Sone H, Yoshimura Y, and Yamada N. A hierarchical regression model for dietary data adjusting for covariates measurement error by regression calibration: An application to a large prospective study for diabetic complications. Japanese Journal of Biometrics 2010; 31: 49-62.
  149. Saito M, Iwata N, Kawakami N, Matsuyama Y, Ono Y, Nakane Y, Nakamura Y, Tachimori H, Uda H, Nakane H, Watanabe M, Naganuma Y, Furukawa TA, Hata Y, Kobayashi M, Miyake Y, Takeshima T, Kikkawa T; World Mental Health Japan 2002?2003 Collaborators. Evaluation of the DSM-IV and ICD-10 criteria for depressive disorders in a community population in Japan using item response theory. International Journal of Methods in Psychiatric Research 2010; 19: 211-222.
  150. Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, Takayasu K, Hayashi N, Makuuchi M, Matsuyama Y and Monden M. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatology Research 2010 40; 1043-1059.
  151. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Journal of Gastroenterology 2010; 45: 1272-1282.
  152. Matsuyama Y. A comparison of the results of intent-to-treat, per-protocol, and g-estimation in the presence of non-random treatment changes in a time-to-event non-inferiority trial. Statistics in Medicine 2010; 29: 2107-2116.
  153. Takao T, Idea T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y. The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up. Diabetes Research and Clinical Practice 2010; 89: 296-302.
  154. Shimizu F, Taguri M, Harada Y, Matsuyama Y, Sase K, Fujime M. Impact of dry ejaculation caused by highly selective alpha1A-blocker: Randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men. Journal of Sexual Medicine 2010; 7(3): 1277-1283.
  155. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, and Makuuchi M for the Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: Propensity score analysis. American Journal of Roentgenology 2010; 194: 830-837.
  156. Yasunaga H, Matsuyama Y, Ohe K; Japan Surgical Society. Effects of hospital and surgeon volumes on operating times, postoperative complications, and length of stay following laparoscopic colectomy. Surgery Today 2009; 39(11): 955-961.

Conference

  1. Takada M, Shigehira Saji, Takayuki Ueno, Norikazu Masuda, Hiroshi Ishiguro, Takanori Ishida, Toshiaki Saeki, Shigeru Imoto, Shinji Ohno, Yoshinori Ito, Hiroji Iwata, Tomoharu Sugie, Kenjiro Aogi, Hirofumi Mukai, Shin Takayama, Nobuaki Sato, Yuichiro Kai, Masahiro Kitada, Yutaka Matsuyama, Masakazu Toi. Adjuvant S-1 plus endocrine therapy for estrogen receptor-positive, HER2-negative, primary breast cancer: update overall survival analysis from the POTENT trial. SABCS2022. 45th San Antonio Breast Cancer Symposium. 12/6/2022 - 12/10/2022.
  2. Yoshikuni Kawaguchi, Ryuichi Kita, Toru Kimura, Tadatoshi Takayama, Namiki Izumi, Masatoshi Kudo, Shuichi Kaneko, Naoki Yamanaka, Masahumi Inomata, Mitsuo Shimada, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo, Kiyoshi Hasegawa. Medical Expenditures and Treatment Efficacy of Patients who had Initial Hepatocellular Carcinoma and Underwent Surgery or Radiofrequency Ablation: Accompanying Research of the SURF Trial. ESMO2022.
  3. Tatsuya Yamashita, Yoshikuni Kawaguchi, Shuichi Kaneko, Tadatoshi Takayama, Namiki Izumi, Naoki Yamanaka, Masatoshi Kudo, Mitsuo Shimada, Masafumi Inomata, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo, Kiyoshi Hasegawa. A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF-Cohort Trial): Analysis of overall survival. 2022 ASCO Annual Meeting (June 3 - June 7, 2022).
  4. Takashi Masuda, Yuichi Endo, Kiyoshi Hasegawa, Yoshikuni Kawaguchi, Tadatoshi Takayama, Namiki Izumi, Naoki Yamanaka, Masatoshi Kudo, Mitsuo Shimada, Shuichi Kaneko, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Masafumi Inomata, Norihiro Kokudo: SURF trial group. Comparative study of laparoscopic hepatectomy, open hepatectomy, and percutaneous radiofrequency ablation for small hepatocellular carcinoma: an ancillary study of randomized controlled trial (SURF trial). IHPBA(International HPB association world congress)24, Supp 1, S134, 2021.
  5. Masatoshi Kudo, Kiyoshi Hasegawa, Yoshikuni Kawaguchi, Tadatoshi Takayama, Namiki izumi, Naoki Yamanaka, Mitsuo Shimada, Masafumi Inomata, Shuichi Kaneko, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo. A multicenter randomized controlled trial to evaluate the efficacy of SUrgery vs. RadioFrequency ablation for small hepatocellular carcinoma (SURF TRIAL): Analysis of Overall Survival. 2021 ASCO Annual Meeting. June 4-8, 2021
  6. Sawamoto R, Matsuyama Y. Standardized mortality ratio-weighted power prior approach for covariate-adjusted borrowing of historical control data. 2021 Joint Statistical Meetings, Online. Aug 2021.
  7. Takeuchi Y, Hagiwara Y, Matsuyama Y. Marginal structural Cox models in nested case-control studies with time-varying treatments. 42nd Conference of the International Society for Clinical Biostatistics. Online. Jul 2021.
  8. Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
  9. Takeuchi Y. Kumamaru H, Hagiwara Y, Matsui H, Yasunaga H, Miyata H, Matsuyama Y, Risk of Sodium-Glucose Cotransporter-2 Inhibitor on the Incidence of Urinary Tract Infection among Diabetic Patients in Japan: A Nationwide Cohort Study (poster presentation). ICPE All Access. Online. Sep 2020.
  10. Kashiwabara K, Matsuyama Y. Treatment effect estimation in an efficient adaptive design: comparison with the exact estimation method. 40th Annual Conference of the ISCB 2019, 14-18 July, Leuven, Belgium.
  11. Satoi S, Unno M, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H, Takahashi S, Sho M, Ueno H, Yamamoto H, Kosuge T. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (Randomized phase II/III trial; Prep-02/JSAP-05). ASCO 2019, May 31-June 4, Chicago, USA
  12. Izumi N, Hasegawa K, Nishioka Y, Takayama T, Yamanaka N, Kudo M, Shimada M, Inomata M, Kaneko S, Baba H, Koike K, Omata M, Makuuchi M, Matsuyama Y, Kokudo N. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). ASCO 2019, May 31-June 4, Chicago, USA. J Clin Oncol 37, 2019 (suppl; abstr 4002)
  13. Matsumoto I, Unnno M, Motoi F, Satoi S, Aosasa S, Shirakawa H, Wada K, Matsuyama Y. The feasibility and efficacy of neoadjuvant chemotherapy for resectable pancreatic cancer: A randomized phase II/III trial from Japan. 48th World Congress of Surgery WCS 2019, Krakow, Poland, 14 August 2019.
  14. Kashiwabara K, Matsuyama Y. Point and interval estimation in an efficient adaptive design of flexible sample size determination. At: Joint International Society for Clinical Biostatistics and Australian Statistical Conference 2018, Melbourne, Australia, 26–30 August, 2018. Abstr P4.
  15. Kozuma Ken, Kozuma Kayoko, Shinozaki T, Kashiwabara K, Oba K, Xience PMS Group, PROMUS Element/Element Plus PMS Group, Matsuyama Y. Predictors for angiographic edge restenosis of 2nd generation drug-eluting stents: Integrated angiographic analyses from the post-marketing surveillance studies of everolimus-eluting stents in Japan. ESC Congress 2018, Munich, Germany, August 25-29, 2018
  16. Hagiwara Y, Shinozaki T, Matsuyama Y. G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome. 29th International Biometric Conference. Barcelona, Spain. July 2018. CS41.1.
  17. Kozuma Kayoko, Shinozaki T, Kozuma Ken, Kashiwabara K, Oba K, Aoki J, Awata M, Nanasato M, Shiode N, Tanabe K, Yamaguchi J, Kimura T, Matsuyama Y. Impact of residual stenosis on the angiographic edge restenosis of 2nd generation drug-eluting stents (A quantitative coronary angiography from the post-marketing surveillance studies of cobalt-chromium everolimus-eluting stent in Japan). EuroPCR 2018, Paris, France, May 22-25, 2018
  18. Kashiwabara K, Matsuyama Y. A reasonable adaptive Simon’s two-stage design. At: 38th Annual Conference of the International Society for Clinical Biostatistics, Vigo, Spain, 9–13 July, 2017. Abstr PC2-M29.
  19. Kashiwabara K, Matsuyama Y. An efficient adaptive sample size determination via working sequential designs for confirmatory clinical trials. At: 28th International Biometric Conference, Victoria, Canada, 10–15 July, 2016. Abstr 2465136.
  20. Kashiwabara K, Matsuyama Y. Adaptive group sequential test without predetermination of total and group sample sizes. At: 2014 Joint Statistical Meetings, Boston, MA. August 2–7, 2014. Abstract 312721.
  21. Takeuchi Y, Shinozaki T, Hiramatsu T, Matsuyama Y. The Risk of Liver Injury Associated with Antibiotics Adjusted for Change of Treatments by Inverse Probability of Censoring Weighting (poster presentation). 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Montreal. Aug 2017.
  22. Takeuchi Y, Shinozaki T, Matsuyama Y. Stratified proportional hazards model in self-controlled design: validity and extension of sequential symmetry analysis (poster presentation). Society for Epidemiologic Research 50th Annual Meeting. Seattle. Jun 2017.
  23. Nozaki T, Kashiwabara K, Shinozaki T, Oba K, Matsuyama Y, Ota E, Mori R. A network meta-analysis of prophylactic antibiotics for preventing post-cesarean endometritis. At: The 24th Cochrane Colloquium, Seoul, Korea. October 23–27, 2016.
  24. Hagiwara Y, Shinozaki T, Matsuyama Y. Estimation of modified effectiveness in randomized trials with subsequent treatments using dynamic marginal structural models. UK Causal Inference Meeting 4th annual meeting, London, England, April 13, 2016. P18.
  25. Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O, The Liver Cancer Study Group of Japan. Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan. 2015 ASCO Annual Meeting, May 29 – June 2, 2015 at the McCormick Place Convention Center in Chicago, Illinois.
  26. Unno M, Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Furukawa T, Ishida K, Takase K, Matsuyama Y, Nakagawa K, Katayose Y. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus surgery-first for resectable pancreatic carcer (Prep-02/JSAP05). 2015 ASCO Annual Meeting, May 29 – June 2, 2015 at the McCormick Place Convention Center in Chicago, Illinois.
  27. Matsumoto Y, Umemura S, Kobayashi N, Tanaka Y, Sasaki C, Shimizu K, Ogawa A, Kinoshita H, Matsuyama Y, Morita T, Goto K, Ohe Y. Early palliative care for patients with metastatic lung cancer receiving chemotherapy: a feasibility study of a nurse-led screening program. 14th World Congress of the European Association for Palliative Care. 5-8 May 2015, Copenhagen, Denmark.
  28. Shinozaki T, Matsuyama Y. Doubly robust standardization in cohort studies with a binary exposure and censored events. At: 2015 Joint Statistical Meetings, Seattle, WA. Aug 2015. Abstract 316644.
  29. Tajima R, Ohashi Y, Ueshima H, Matsuyama Y. Comparison of Bayesian Regression Methods for Sparse Epidemiologic Data Analysis. Joint Statistical Meeting 2015, Seattle, 10 Aug 2015.
  30. Kawahara T, Matsuyama Y. Doubly Robust Risk Estimation in the Presence of Informative Censoring Incorporating Time-Dependent Covariates. Joint Statistical Meeting 2015, Seattle, 10 Aug 2015.
  31. Kobayashi A, Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Bandai Y, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Watanabe T, Makuuchi M, Kokudo N. A randomized controlled trial evaluating efficacy of adjuvant oral uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases: The UFT/LV study. 50th American Society of Clinical Oncology (ASCO) annual meeting.(abstract 3584). May 30-June 3, 2014, McCormick Place, Chicago, Illinois.
  32. Nakamura M, Muramatsu T, Yokoi H, Okada H, Ochiai M, Suwa S, Matsuyama Y, Nanto S. J-DESsERT 3-Year Outcomes: Largest randomized trial stratified by diabetes mellitus presence, comparing sirolimus and paclitaxel eluting stents. Transcatheter Cardiovascular Therapeutics (TCT). October 27-November 1, 2013, The Moscone Center San Francisco, CA, USA.
  33. Shinozaki T, Matsuyama Y. Robust and efficient estimation of structural nested mean models in randomized trials with partial compliance using generalized method of moments. The XXVIIth International Biometric Conference, Florence, Italy. July 10, 2014. Poster Group 2, Abstract 35.
  34. Shinozaki T, Matsuyama Y, Ohashi Y. "Sensitivity analysis in randomized trials with partial compliance using generalized methods of moments applied to structural nested models" 34th Annual Conference of the International Society for Clinical Biostatistics, Munich, Germany, August 28, 2013. Abstract C34.2.
  35. Yokota I, Matsuyama Y, Ohashi Y. Extension on a landmarking model using a fractional polynomial function for dynamic prediction. 34th Annual Conference of the International Society for Clinical Biostatistics, Munich, Germany, August 25-27, 2013. Abstract P136.
  36. Hideki Kitahara, Katsuhisa Waseda, Kenji Sakamoto, Ryotaro Yamada, Ching-Chang Huang, Daisaku Nakatani, Kenji Sakata, Osami Kawarada, Paul Yock, Yutaka Matsuyama, Hiroyoshi Yokoi, Masato Nakamura, Toshiya Muramatsu, Shinsuke Nanto, Peter Fitzgerald, Yasuhiro Honda. Impact of stent edge plaque burden on lumen preservation after DES implantation: A 3D-IVUS analysis from the J-DESsERT trial. Transcatheter Cardiovascular Therapeutics (TCT) 2012 (October 22-26) in Miami Beach Convention Center, Miami, USA.
  37. Ching-Chang Huang, Hideki Kitahara, Katsuhisa Waseda, Kenji Sakamoto, Ryotaro Yamada, Osami Kawarada, Kenji Sakata, Daisaku Nakatani, Paul Yock, Yutaka Matsuyama, Hiroyoshi Yokoi, Toshiya Muramatsu, Masato Nakamura, Shinsuke Nanto, Peter Fitzgerald, Yasuhiro Honda. Impact of IVUS-detected calcification on subsequent neointimal hyperplasia after drug-eluting stent implantation: An IVUS substudy of the J-DESsERT trial. Transcatheter Cardiovascular Therapeutics (TCT) 2012 (October 22-26) in Miami Beach Convention Center, Miami, USA.
  38. Takao T, Matsuyama Y, Ide T, Yanagisawa H, Kikuchi M, Kawazu S. Relationships of visit-to-visit variability and time-to-effect in systolic blood pressure to the risks of nephropathy and retinopathy in type 2 diabetes. European Association for the Study of Diabetes (EASD) 2012, October 1-5, Berlin, Germany.
  39. Yokota I, Matsuyama Y, Ohashi Y. Comparison of the tests for interval-censored survival data with differential assessment times. XXVIth International Biometrics Conference 2012, Kobe, Japan. August 26 - 31, 2012. Abstract P-3-24.
  40. Sakamaki K, Matsuyama Y, Ohashi Y. Graphical procedures for gatekeeping applications. XXVIth International Biometrics Conference 2012, Kobe, Japan. August 26 - 31, 2012. Abstract P-3-20.
  41. Yoshida M, Matsuyama Y. A stochastic curtailment method based on the widthed log-rank test for delayed treatment effects. XXVIth International Biometrics Conference 2012, Kobe, Japan. August 26 - 31, 2012. Abstract P-3-8.
  42. Shinozaki T, Matsuyama Y, Iimuro S, Ohashi Y, and Ito H. Estimating causal effects of atorvastatin in elderly diabetics. XXVIth International Biometrics Conference 2012, Kobe, Japan. August 26 - 31, 2012. Abstract P-1-24.
  43. Shinozaki T, Matsuyama Y, Iimuro S, Ohashi Y, and Ito H. Estimation of controlled direct effects for dynamic treatment regimes. 2012 Joint Statistical Meetings, San Diego, USA, July 28 - August 2, 2012. Abstract #306152.
  44. Sakamaki K, Matsuyama Y, Ohashi Y. Flexible multiple testing procedures based on resampling methods for gatekeeping applications. 2012 Joint Statistical Meetings, San Diego, USA, July 28 - August 2, 2012. Abstract #306148.
  45. Yokota I, Matsuyama Y, Ohashi Y. Simulation studies on the analysis of interval-censored survival data with differential assessment times. 2012 Joint Statistical Meetings, San Diego, USA, July 28 - August 2, 2012. Abstract #305521.
  46. Yoshida M, Matsuyama Y. A group sequential method based on the widthed log-rank test for delayed treatment effects. 2012 Joint Statistical Meetings, San Diego, USA, July 28 - August 2, 2012. Abstract #304784.
  47. Taguri M, Matsuyama Y, Ohashi Y. Doubly robust estimation of the generalized impact fraction. East Asia Regional Biometric Conference 2012. February 2-3, 2012, Seoul National University Hoam Convention Center, Seoul, Korea.
  48. Saiura A, Ueno H, Kosuge T, Matsuyama Y, Ishii H, Nakao A, Doi R, Tanaka M. A phase II trial of gemcitabine and S-1 therapy in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer (JSAP-03). ASCO 2012 Gastrointestinal Cancers Symposium (January 19 - 21, 2012). Abstract #88144
  49. Ng CFS, Matsuyama Y, Ohashi, Y. Relative incidence of adverse events in disseminated intravascular coagulation patients using modified self-controlled case series method. The 32nd annual Conference of the International Society for Clinical Biostatistics (ISCB). August 21-25 in Ottawa, Canada. Abstract C134.
  50. Shinozaki T, Matsuyama Y, Ohashi Y. Estimating controlled direct effects for time-varying treatments using structural nested mean models. 2011 Joint Statistical Meetings, Miami, USA, August 1 - August 5, 2011. Abstract 360.
  51. Matsuyama Y. A comparison of the results of intent-to-treat, per-protocol, and g-estimation in the presence of nonrandom treatment changes in a time-to-event non-inferiority trial. 2010 Joint Statistical Meetings, Vancouver, Canada, August 1 - August 5, 2010. Abstract 501.
  52. Takeuchi A, Matsuyama Y, Nitta H, Ono M. Adjustment of regional differences using generalized additive mixed model to estimate the health effect of PM2.5. 2010 Joint Statistical Meetings, Vancouver, Canada, August 1 - August 5, 2010. Abstract 530.
  53. Taguri M, Matsuyama Y, Ohashi Y. Model selection for causal parameters in structural mean models based on a quasi-likelihood. 2010 Joint Statistical Meetings, Vancouver, Canada, August 1 - August 5, 2010. Abstract 360.
  54. Yoshida M and Matsuyama Y. A stochastic curtailment method based on the widthed log-rank test for delayed treatment effects. The 31h annual Conference of the International Society for Clinical Biostatistics (ISCB). 29July-2August 2010, Montpellier, France. Abstract P1-2715.
  55. Isayama H, Yasuda I, Ryozawa S, Maguchi H, Igarashi Y, Matsuyama Y, Katanuma A, Hasebe O, Irisawa A, Itoi T, Mukai H, Arisaka Y, Okushima K, Uno K, Kida M, Tamada K. The result of Japanese multicenter randomized trial of endoscopic stenting for the non-resection pancreatic head cancer. American Society for Gastrointestinal Endoscopy. McCormick Place in Chicago, IL, May 30 - June 4, 2009
  56. Taguri M, Matsuyama Y, Ohtsu H, Harada A, Ohashi Y, Ueshima H. Stroke incidence attributable to metabolic risk factors stratified by obesity: Using doubly robust estimators of the population attributable fraction. The XVIII IEA World Congress of Epidemiology, Porto Alegre, Brazil, 20/September-24/September, 2008
  57. Takeuchi A, Matsuyama Y, Omori T, Ono M, and Nitta H. Effects of ambient air pollution (PM2.5) on daily mortality in Japanese 20 cities. The XXIVth International Biometric Conference, Dublin, Ireland, 13/July-15/July, 2008
  58. Yanaihara H, Deguchi N, Fuji K, Yasunaga H, Matsuyama Y, and Ohe K. Influence of hospital and surgeon volume on operative time, blood loss, and perioperative complications in radical nephrectomy: The results from nationwide survey in Japan. American Urological Association Annual Meeting. Journal of Urology 179(4) Supplement: 29, 2008 Orlando, Florida 17-22 May 2008
  59. Kosuge T, Ueno H, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, and Tanaka M. A randomized phase III study comparing gemcitabine monotherapy with observation in patients with resected pancreatic cancer. The 14th European Cancer Conference. 23September-27September 2007, Barcelona, Spain.
  60. Sugihara M, Matsuyama Y, Matsushita Y, and Orihashi Y. Estimation of causal effects using IPTW methods based on time-dependent propensity score for survival data. The 28th annual Conference of the International Society for Clinical Biostatistics (ISCB). 29July-2August 2007, Alexandroupolis, Greece.
  61. Tanaka S, Matsuyama Y, and Ohashi Y. Estimating surrogate endpoints defined by principal causal effects. 2007 Joint Statistical Meetings, Salt Lake City, Utha, July 29 - August 2, 2007. Abstract 123.
  62. Tanaka S, Tanaka S, Matsuyama Y, and Yamamoto S. Inverse probability widthed estimators in the stratified nested case-control sampling method. 2007 Joint Statistical Meetings, Salt Lake City, Utha, July 29 - August 2, 2007. Abstract 220.
  63. Uemura K, Matsuyama Y, and Ohashi Y. Sample size re-calculation methods in clinical trials based on the observed treatment difference at an interim look. XXIIIrd International Biometrics Conference. Montreal, Canada, 17/July-21/July, 2006.
  64. Tanaka Y, Matsuyama Y, Ohashi Y and MEGA Study group. Estimation of treatment effect adjusting for non-compliance using the intensity score method - an application to a large primary prevention study for coronary events -. XXIIIrd International Biometrics Conference. Montreal, Canada, 17/July-21/July, 2006.
  65. Morita S and Matsuyama Y. Estimation of the average causal effect among subgroups defined by posttreatment variables. The 25th annual Conference of the International Society for Clinical Biostatistics (ISCB). 15- 19, August, 2004, Leiden, The Netherlands. Cont. 2003: 24(3S), 56S.
  66. Teramukai S, Matsuyama Y and Mizuno S. Exploring between study heterogeneity in individual patient data meta-analysis. The 3rd joint meeting of the International Society for Clinical Biostatistics (ISCB) and Society for Clinical Trials (SCT). London, UK. 20th-24th, July, 2003 Controlled Clinical Trials. 2003: 24(3S), 112S.
  67. Matsuyama Y and Yamaguchi Y. Estimation of the marginal survival time in the presence of competing risks. The 3rd joint meeting of the International Society for Clinical Biostatistics (ISCB) and Society for Clinical Trials (SCT). London, UK. 20th-24th, July, 2003 Controlled Clinical Trials. 2003: 24(3S), 56S.
  68. Kikuchi M, Matsuyama Y, and Ide T. The cause and effect relationship between pancreatic ?-cell impairment or insulin resistance and the natural history of development of type 2 diabetes in the employees of a trade firm in Tokyo. 8th Annual Meeting of the European Association for the Study of Diabetes. Budapest, Hungary, 1-5/September, 2002
  69. Matsuyama Y. Sensitivity analysis for the estimation of rates of change with non-ignorable drop-out: An application to a randomized clinical trial of the vitamin D3. XXIst International Biometrics Conference. Freiburg, Germany, 21/July-26/July, 2002 Proceedings. 2002:132.
  70. Sato T and Matsuyama Y. Marginal structural models as a tool for standardization. XXIst International Biometrics Conference. Freiburg, Germany, 21/July-26/July, 2002 Proceedings. 2002:29.

Symposium

  1. Yutaka Matsuyama. Measuring PROs for people with Parkinson’s in clinical trials. Takeda Expert Conference on Parkinson’s Disease. Tokyo. 2020/12/12.
  2. Shinozaki T, Matsuyama Y. (November 2014). “Doubly robust estimation of a marginal structural model in the exposed population.” At: Kyoto International Conference on Modern Statistics in the 21st Century, Kyoto, Japan. Chair: Manabu Iwasaki. (Invited)
  3. Matsuyama Y. Semiparametric estimation of treatment effect in a randomized clinical trial with missing data. International Symposium Incomplete Data Analysis and Causal Inference, Osaka University, 22-23 September 2013.
  4. Matsuyama Y and Tanaka Y. Estimation of treatment effect adjusting for non-compliance using the intensity score method. 科学研究費補助金(基盤研究 (A) (1))シンポジウム「不完全データ解析とその周辺」 東京.2006/1/23.

Publication

  1. Shinozaki T, Matsuyama Y. Analysis on Real-World Data: An Overview. Epidemiologic Research on Real-World Medical Data in Japan. Springer Nature Vol2, 77-88, 2022.
  2. Shinozaki T, Matsuyama Y. Data analysis on real world data: an overview. In: Sudoh, O. (editor). Epidemiologic Research on Real World Medical Data in Japan. Switzerland: Springer International Publishing, 2019 (forthcoming).

TOP